Nature Reviews Cancer Publishes ALL Review Covering 40-Plus Molecular Subtypes
Updated
Updated · Nature.com · Jul 2
Nature Reviews Cancer Publishes ALL Review Covering 40-Plus Molecular Subtypes
3 articles · Updated · Nature.com · Jul 2
Summary
Nature Reviews Cancer published a review by I. Iacobucci and C.G. Mullighan summarizing recent advances in acute lymphoblastic leukaemia biology, with emphasis on genomic and epigenomic discoveries reshaping the field.
More than 40 molecular subtypes have now been identified, especially in B-cell precursor ALL, refining classification and increasingly guiding risk stratification, treatment selection and disease monitoring.
Large-scale genomic studies are also redefining T-cell ALL beyond older immunophenotypic categories, uncovering biologically distinct subtypes driven by coding and noncoding alterations.
The review says many lesions are clinically actionable—notably kinase-activating changes enabling targeted therapies—but resistance remains a central obstacle through clonal evolution, secondary mutations and adaptive transcriptional or epigenetic reprogramming.
It argues that integrating genetic, transcriptional, 3D genome and epigenetic data could improve prognosis assessment and therapeutic outcomes across ALL.
With cancer care costs soaring, is precision medicine widening the survival gap between rich and poor?
Beyond killing cancer cells, can we manipulate their environment to put them to sleep permanently?
As AI builds patient 'digital twins', who is liable if the simulation-guided treatment fails?
Redefining Cancer: How Molecular Subtyping and AI-Driven Multi-Omics Are Transforming Precision Oncology in 2025
Overview
Cancer classification is rapidly evolving, moving beyond traditional methods to focus on molecular subtyping. This shift is driven by detailed analysis of tumors’ genetic and molecular features, revealing that cancers once seen as single diseases actually consist of multiple distinct subtypes. Projects like The Cancer Genome Atlas have mapped these differences, fundamentally changing our understanding of cancer. Recognizing these unique molecular profiles helps explain why patients with similar diagnoses can have very different outcomes and responses to treatment, paving the way for more precise and effective therapies tailored to each individual’s cancer.